12 research outputs found
Everesting challenge attempt strategy: A case study
The Everesting challenge (repeat any hill, anywhere in the world, until you climb an altitude of 8848 m; the equivalent of M. Everest) is becoming an increasingly popular challenge. The physical and metabolic stress to which the body is exposed during this type of exercise is unusual and it is also particularly challenging for coaches, trainers and sport nutritionists. The aim of this study is to analyse the parameters and key details necessary to optimize a 10-week training protocol for an ultra-endurance performance like the Everesting challenge. An ex-Ă©lite cyclist, trained individual (male; 26 years; 181 cm; 71,7 kg; 21,9 BMI) followed a 10 weeks training and nutrition program to reach his peak performance and attempt the challenge. Body composition analysis checks (body weight, body circumferences, skinfold thickness and bioimpedance analysis) and performance tests (Conconi, Functional Threshold Power, Maximum Lactate Steady State) were planned at week 1, 5 and 10. After 10 weeks FTP increased from 245 to 267 W and at MLSS from 252 W to 270 W. Body weight decreased from 71,7 kg to 68,3 kg and body fat from 10,7% to 6,8 % (Jackson-Pollock 7 sites). The individual was able to accomplish the Everesting challenge concluding his ride in 13h34m27s, average power 162 W, average heart rate 139 bpm, 7685 kcal consumed. 10 weeks of strategically planned nutrition and training program may be sufficient to prepare an Ă©lite athlete or a well-trained individual to attempt an ultra-endurance challenge like the Everesting
Impact of 24 weeks of strength training coupled to endurance training on endurance performance (hero dolomites 2019)
Despite reports are still equivocal, in recent years different studies reported how strength training could impact positively on endurance performance. The aim of this study was to evaluate the impact of a long-term strength coupled to endurance training protocol in comparison with endurance training protocol on cycling performance. 14 trained amateurs' cyclists (males; 27,03 ± 3,75 years; 177,15 ± 5,69 cm; 69,67 ± 8,53 kg; 22,2 ± 1,67 BMI) that completed the Hero Dolomites 2018 competition and signed to the 2019 edition (86 km, 4500 m) participated to the study. 7 of them (treated) followed a 24 weeks strength training coupled to endurance training program to increase performance, the other (untreated) followed their endurance training routines without any specific resistance training protocol. FTP (Functional Threshold Power) test and 1RM (One Repetition Maximum) test (barbell squat and leg press 45°) were planned at week 1, week 8, week 16 and week 24. 2019 race times were compared to 2018 once. Treated individuals showed increased strength (barbell squat: +29,7 ± 7,8 kg; leg press 45°: +53,5 ± 13,1 kg) and FTP (+23,2 ± 9,3 W) from week 1 to week 24. Both treated and untreated individuals improved their race time from 2018 to 2019 (treated: -51,4 ± 24,6 m; untreated: -11,8 ± 14,4 m). Treated individuals improved significantly race time from 2018 compared to untreated individuals (p<0,05). Structured and periodized strength sessions can be incorporated and maintained for the entire duration of a 24 weeks training program impacting positively on endurance performance
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
BACKGROUND:
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes.
METHODS:
We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization.
RESULTS:
During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events.
CONCLUSIONS:
Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)
Prognostic value of total ischemic burden in patients with stable ischemic heart disease.
Valutazione della ripetibilit\ue0 del test da sforzo in pazienti con cardiopatia ischemica
Platelet alpha 2-adrenoceptor modifications induced by long-term treatment with indapamide in essential hypertension.
The effect of long-term treatment with indapamide in platelet alpha 2-adrenoceptors has been evaluated in 10 patients with essential hypertension, in a double-blind, cross-over study with placebo. After three months of therapy, indapamide significantly reduced mean blood pressure (from 137 +/- 12 to 116 +/- 6 mm Hg, p less than 0.001), whereas heart rate did not change (from 72 +/- 8 to 73 +/- 7 beats/minute). At the same time, platelet alpha 2-adrenoceptor number increased (from 168.2 +/- 48.4 to 256.8 +/- 14.5 fmol/mg protein, p less than 0.02), whereas the dissociation constant did not change (from 3.79 +/- 2.9 to 4.97 +/- 4.48). The plasma norepinephrine level was significantly reduced after long-term treatment with indapamide (from 275 +/- 118 to 210 +/- 56 pg/ml, p less than 0.02). These results bring about an inhibition of norepinephrine release from sympathetic nerve endings with a likely secondary increase of the number of platelet alpha 2-adrenoceptors
Chemical variation of surface water and groundwater in relation to water balance in the watershed of El Pescado Creek (Central-Eastern Argentina)
Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial
Background-The independent prognostic impact of diabetes mellitus (DM) and prediabetes mellitus (pre-DM) on survival outcomes in patients with chronic heart failure has been investigated in observational registries and randomized, clinical trials, but the results have been often inconclusive or conflicting. We examined the independent prognostic impact of DM and pre-DM on survival outcomes in the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial.Methods and Results-We assessed the risk of all-cause death and the composite of all-cause death or cardiovascular hospitalization over a median follow-up period of 3.9 years among the 6935 chronic heart failure participants of the GISSI-HF trial, who were stratified by presence of DM (n= 2852), pre-DM (n= 2013), and non-DM (n= 2070) at baseline. Compared with non-DM patients, those with DM had remarkably higher incidence rates of all-cause death (34.5% versus 24.6%) and the composite end point (63.6% versus 54.7%). Conversely, both event rates were similar between non-DM patients and those with pre-DM. Cox regression analysis showed that DM, but not pre-DM, was associated with an increased risk of all-cause death (adjusted hazard ratio, 1.43; 95% CI, 1.28-1.60) and of the composite end point (adjusted hazard ratio, 1.23; 95% CI, 1.13-1.32), independently of established risk factors. In the DM subgroup, higher hemoglobin A1c was also independently associated with increased risk of both study outcomes (all-cause death: adjusted hazard ratio, 1.21; 95% CI, 1.02-1.43; and composite end point: adjusted hazard ratio, 1.14; 95% CI, 1.01-1.29, respectively).Conclusions-Presence of DM was independently associated with poor long-term survival outcomes in patients with chronic heart failure